Parabilis Medicines is ambitious, but it has Regeneron on its side already.
It has been a banner year for biotech buyouts, and these are two of the prime targets.
Viking Therapeutics aspires to take market share from both Eli Lilly and Novo Nordisk, and it might succeed.
Intellia's CRISPR pipeline and Omeros's newly approved therapy each bring unique risk and reward profiles, see how their ...
In interviews as well as a panel at BIO’s annual meeting, investors and life sciences bankers predicted an acceleration in ...
As AI transforms biology, longevity startups are attracting investors, advancing toward clinical milestones, and reshaping ...
IBB, one of the largest exchange-traded funds focused on biotechnology, manages approximately $8.28 billion in assets and ...
23d
‘Buying stuff like it’s going out of fashion’: Biotech M&A on track for best year since pre-Covid
Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking in 2026 is off to a strong start.
Three mid-cap biotechs have become prime acquisition targets, but only one offers what big pharma is hunting for most.
Kardigan (KARD) didn’t just raise $400 million. The heart-drug developer sent a new signal to biotech investors about what ...
The new outfit, called Saturnus Bio, was announced today by Merck KGaA, and will focus on developing medicines for rare ...
Biopharma dealmaking is driven by pressure to top up drug pipelines ahead of major patent expirations later this decade.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results